

In the Claims

Please replace all prior versions, and listings, of claims in the application with the following list of claims:

Please cancel claims 4-7, 9-14, 18-19, 21-39, 44-61, 63-66, 68-71, 73-81, 84-96, and 100-114. Please amend claims 8, 20, 43, 67, and 97.

1. (Original) A method for characterizing an ovarian cell, the method comprising:
determining the presence or absence of a CD43 molecule in an ovarian cell of a subject to characterize the ovarian cell.
2. (Original) The method of claim 1, wherein the method is diagnostic and wherein the presence of a CD43 molecule in the ovarian cell indicates that the subject has an ovarian tumor.
3. (Original) The method of claim 1, wherein the method is prognostic.
- 4-7. (Cancelled)
8. (Currently amended) The method of[[any one of]] claim[[s]] 1[[-7]], wherein determining the presence or absence of a CD43 molecule is done in the presence of a CD43 binding molecule.
- 9-14. (Cancelled)
15. (Original) A method of treating a subject having or at risk of having a tumor, comprising:
administering to a subject in need of such treatment one or more CD43 inhibitors in an effective amount to treat the tumor.

Serial No.: Not yet assigned
Conf. No.: Not yet assigned

- 4 -

Docket No.: M0765.70064US01
Art Unit: Not yet assigned

16. (Original) The method of claim 15, wherein the CD43 inhibitor is a CD43 nucleic acid binding molecule.

17. (Original) The method of claim 16, wherein the CD43 nucleic acid binding molecule is an hnRNP-K molecule.

18-19. (Cancelled)

20. (Currently amended) The method of claim 15, wherein the CD43 inhibitor is transcription factor.

21-39. (Cancelled)

40. (Original) The method of claim 15, wherein the tumor is a solid tumor selected from the group consisting of: biliary tract cancer, brain cancer (including glioblastomas and medulloblastomas), breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric cancer, intraepithelial neoplasms, including Bowen's disease and Paget's disease, liver cancer, lung cancer, lymphomas, including Hodgkin's disease and lymphocytic lymphomas, neuroblastomas, oral cancer, including squamous cell carcinoma, ovarian cancer, including those arising from epithelial cells, stromal cells, germ cells and mesenchymal cells, pancreatic cancer, prostate cancer, rectal cancer, renal cancer including adenocarcinoma and Wilms tumor, sarcomas, including leiomyosarcoma, rhabdomyosarcoma, liposarcoma, fibrosarcoma and osteosarcoma, skin cancer, including melanoma, Kaposi's sarcoma, basocellular cancer and squamous cell cancer, testicular cancer, including germinal tumors (seminomas, and non-seminomas such as teratomas and choriocarcinomas), stromal tumors and germ cell tumors, and thyroid cancer, including thyroid adenocarcinoma and medullary carcinoma.

41. (Original) The method of claim 15, wherein the tumor is a non-solid tumor selected from the group of hematological neoplasms including: acute or chronic lymphocytic and myelogenous leukemia, multiple myeloma, AIDS associated leukemias and adult T-cell lymphoma/leukemia.

42. (Original) The method of claim 15, wherein the tumor is ovarian cancer.

43. (Currently amended) The method of[[any one of]] claim[[s]] 15[[-42]], further comprising administering one or more anti-tumor therapy.

44-61. (Cancelled)

62. (Original) A method for assessing the regression or progression of an ovarian tumor in a subject with comprising the steps of:

measuring in a first ovarian cell obtained from the subject, the presence of a CD43 molecule,

measuring in a second ovarian cell obtained from the subject, the presence of a CD43 molecule,

comparing the presence of the CD43 molecule in the first ovarian cell and the second ovarian cell,

wherein a decrease in the presence of the CD43 molecule in the second ovarian cell compared to the first ovarian cell indicates regression of the ovarian tumor, and

wherein an increase in the presence of the CD43 molecule in the second ovarian cell compared to the first ovarian cell indicates progression of the ovarian tumor.

63-66. (Cancelled)

67. (Currently amended) The method of[[any one of]] claim[[s]] 62[[-66]], wherein measuring the presence of a CD43 molecule is done in the presence of a CD43 binding molecule.

68-71. (Cancelled)

72. (Original) A kit for diagnosing an ovarian tumor, comprising:
one or more CD43 binding molecules,
one or more control agents, and
instructions for the use of the CD43 binding molecules, and the control agents in
the diagnosis of an ovarian tumor.

73-81. (Cancelled)

82. (Original) A method of reducing the number of white blood cells in a subject comprising
administering to a subject in need of a reduction in the number of white blood cells, a CD43
inhibitor in an effective amount to reduce the number of white blood cells in said subject.

83. (Original) The method of claim 82, wherein the CD43 inhibitor is a hnRNP-K molecule.

84-96. (Cancelled)

97. (Currently amended) The method of[[any of]] claim[[s]] 82[[-96]], further comprising
administering a second therapy to reduce the number of white blood cells.

98. (Original) A method of inhibiting a CD promoter comprising contacting the CD
promoter with a CD43 inhibitor in an amount effective to inhibit the CD promoter.

99. (Original) The method of claim 98, wherein the CD43 inhibitor is a hnRNP-K molecule.

100-114. (Cancelled)